NovoSeven RT, a new version of Novo Nordisk's bioengineered protein therapy, has obtained FDA clearance to treat bleeding in selected patients with hemophilia. The agency also noted a higher risk of arterial clots in some elderly patients who take the drug for off-label uses.

Full Story:

Related Summaries